Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research7

FiltersClear all

Status

Recruiting4
Active, not recruiting2
Completed1

Study type

Interventional7

Phase

Phase 37
Phase 211
Phase 44
Not applicable3
Not reported2
Phase 11
Phase 2/31

Investigator

Ellen J Scherl4
Aliza B Solomon2
Robbyn Sockolow1

Department

Medicine4
Pediatrics3

Condition

Colitis, Ulcerative7
Breast Neoplasms17
Obesity15
COVID-1912
Overweight12

Show all 50

Intervention type

Drug7
Other1

Sponsor type

Industry7

Start date

to

Has results posted1

Phase 3×Colitis, Ulcerative×Clear all

Showing 1–7 of 7 studiesSort:

Active, not recruitingInterventional · Phase 3NCT04624230 ↗
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Show fewer

Robbyn Sockolow

PI

Intervention: Drug: tofacitinib
Dates: Aug 2021 – Mar 2027 (est.)
Sponsor: Pfizer, Inc.

Ulcerative Colitis

RecruitingInterventional · Phase 3NCT06100289 ↗

An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Aliza B SolomonPI

Intervention: Drug: Vedolizumab IV · Drug: Vedolizumab SC
Dates: Jan 2025 – May 2028 (est.)
Sponsor: Takeda Development Center Americas, Inc.

Ulcerative ColitisCrohn's Disease

RecruitingInterventional · Phase 3NCT06405087 ↗

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Aliza B SolomonPI

Intervention: Drug: Vedolizumab SC · Other: No Intervention
Dates: Oct 2025 – Aug 2030 (est.)
Sponsor: Takeda Development Center Americas, Inc.

Ulcerative ColitisCrohn's Disease

RecruitingInterventional · Phase 3NCT07184996 ↗

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis.

Ellen J ScherlPI

Intervention: Drug: Duvakitug · Drug: Placebo
Dates: Oct 2025 – May 2028 (est.)
Sponsor: Sanofi S.A.

Ulcerative Colitis

RecruitingInterventional · Phase 3NCT07185009 ↗

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ellen J ScherlPI

Intervention: Drug: Duvakitug · Drug: Placebo
Dates: Jan 2026 – Sep 2028 (est.)
Sponsor: Sanofi S.A.

Ulcerative Colitis

Active, not recruitingInterventional · Phase 3NCT07196748 ↗

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

Ellen J ScherlPI

Intervention: Drug: Icotrokinra · Drug: Placebo
Dates: Oct 2025 – Jan 2028 (est.)
Sponsor: Janssen Research & Development, LLC

Colitis, Ulcerative

CompletedInterventional · Phase 3NCT03283085 ↗

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Ellen J ScherlPI

Intervention: Drug: 25 mg Ontamalimab · Drug: 75 mg Ontamalimab
Dates: Feb 2018 – Dec 2023· Results posted
Sponsor: Shire Pharmaceuticals, Inc.

Crohn's DiseaseUlcerative Colitis